Previous studies reported that TP53 mutations may lead to a worse prognosis in TKI-treated NSCLC patients; however, we did not observe significant differences in mDFS between patients with TP53 mutations and those with wildtype TP53 (mDFS=16.0 vs. 20.0 months; HR=1.18; 95% CI, 0.39–3.57; p=0.771) (Figure S4A). Here, TP53 is linked to non-small cell lung carcinoma.